FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899687438> ?p ?o ?g. }

• W2899687438 endingPage "vi18" @default.
• W2899687438 startingPage "vi17" @default.
• W2899687438 abstract "DNA damage caused by TMZ or RT sensitizes tumors to PARP inhibitors, especially in highly replicating tumors (eg, GBM). Pamiparib is a selective PARP1/2 inhibitor with potent PARP trapping that can cross the blood-brain barrier and has shown synergistic cytotoxicity with TMZ in nonclinical experiments. At 60mg BID, the human-equivalent dose-to-trough brain concentrations above the nonclinical efficacy threshold, pamiparib was generally well tolerated and showed antitumor activity in early clinical studies ({type:clinical-trial,attrs:{text:NCT02361723,term_id:NCT02361723}}NCT02361723; {type:clinical-trial,attrs:{text:NCT03333915,term_id:NCT03333915}}NCT03333915). This ongoing dose-escalation/expansion study ({type:clinical-trial,attrs:{text:NCT03150862,term_id:NCT03150862}}NCT03150862) will determine the safety/tolerability and antitumor effects of pamiparib (60mg BID)+RT and/or TMZ. The dose-escalation component consists of three arms. Arm A will establish tolerable duration of pamiparib (2, 4, 6 weeks)+RT in newly diagnosed GBM patients with unmethylated MGMT promoter (unmethyl-GBM). In Arm B, newly diagnosed patients with unmethyl-GBM will receive pamiparib+RT with increasing TMZ doses. Enrollment in Arm B will commence once RP2D for pamiparib+RT is established. In Arm C, patients with recurrent/refractory methylated- or unmethyl-GBM receive pamiparib with increasing TMZ doses. As of 28 March 2018, 15 patients were enrolled (A: 2-wk, n=3; 4-wk, n=6; C: TMZ [40mg], n=6). One DLT (grade 3 nausea) was reported in Arm C. Across arms, pamiparib-related AEs occurring in >3 patients were nausea (n=6) and fatigue (n=5). Two patients experienced three pamiparib-related AEs grade 3 (diarrhea [A: 4-wk, n=1]; fatigue and nausea [C: n=1]). All three resolved with concomitant medication and treatment interruption (A) or discontinuation (C). Of the seven patients with 1 tumor assessment, one (A: 4-wk) achieved an unconfirmed PR; four (A: 2-wk, n=2; 4-wk, n=2) had SD, and two (A: 2-wk, n=1; C: n=1) had PD. Preliminary data suggests pamiparib at 60mg BID is generally well tolerated by patients when administered 4 weeks concurrently with RT for newly diagnosed unmethyl-GBM and when combined with 40 mg TMZ for recurrent/refractory GBM." @default.
• W2899687438 created "2018-11-16" @default.
• W2899687438 creator A5021656597 @default.
• W2899687438 creator A5021793481 @default.
• W2899687438 creator A5023905352 @default.
• W2899687438 creator A5026869480 @default.
• W2899687438 creator A5034837880 @default.
• W2899687438 creator A5035036696 @default.
• W2899687438 creator A5036608249 @default.
• W2899687438 creator A5037535298 @default.
• W2899687438 creator A5044095019 @default.
• W2899687438 creator A5046465813 @default.
• W2899687438 creator A5050035595 @default.
• W2899687438 creator A5056817906 @default.
• W2899687438 creator A5062905847 @default.
• W2899687438 creator A5063511816 @default.
• W2899687438 creator A5076017612 @default.
• W2899687438 creator A5086283695 @default.
• W2899687438 date "2018-11-01" @default.
• W2899687438 modified "2023-10-11" @default.
• W2899687438 title "ACTR-30. PHASE 1B/2 STUDY TO ASSESS THE CLINICAL EFFECTS OF PAMIPARIB (BGB-290) IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY GLIOBLASTOMA (GBM)" @default.
• W2899687438 doi "https://doi.org/10.1093/neuonc/noy148.063" @default.
• W2899687438 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6216180" @default.
• W2899687438 hasPublicationYear "2018" @default.
• W2899687438 type Work @default.
• W2899687438 sameAs 2899687438 @default.
• W2899687438 citedByCount "5" @default.
• W2899687438 countsByYear W28996874382020 @default.
• W2899687438 countsByYear W28996874382021 @default.
• W2899687438 countsByYear W28996874382023 @default.
• W2899687438 crossrefType "journal-article" @default.
• W2899687438 hasAuthorship W2899687438A5021656597 @default.
• W2899687438 hasAuthorship W2899687438A5021793481 @default.
• W2899687438 hasAuthorship W2899687438A5023905352 @default.
• W2899687438 hasAuthorship W2899687438A5026869480 @default.
• W2899687438 hasAuthorship W2899687438A5034837880 @default.
• W2899687438 hasAuthorship W2899687438A5035036696 @default.
• W2899687438 hasAuthorship W2899687438A5036608249 @default.
• W2899687438 hasAuthorship W2899687438A5037535298 @default.
• W2899687438 hasAuthorship W2899687438A5044095019 @default.
• W2899687438 hasAuthorship W2899687438A5046465813 @default.
• W2899687438 hasAuthorship W2899687438A5050035595 @default.
• W2899687438 hasAuthorship W2899687438A5056817906 @default.
• W2899687438 hasAuthorship W2899687438A5062905847 @default.
• W2899687438 hasAuthorship W2899687438A5063511816 @default.
• W2899687438 hasAuthorship W2899687438A5076017612 @default.
• W2899687438 hasAuthorship W2899687438A5086283695 @default.
• W2899687438 hasBestOaLocation W28996874381 @default.
• W2899687438 hasConcept C126322002 @default.
• W2899687438 hasConcept C143998085 @default.
• W2899687438 hasConcept C2777389519 @default.
• W2899687438 hasConcept C509974204 @default.
• W2899687438 hasConcept C71924100 @default.
• W2899687438 hasConceptScore W2899687438C126322002 @default.
• W2899687438 hasConceptScore W2899687438C143998085 @default.
• W2899687438 hasConceptScore W2899687438C2777389519 @default.
• W2899687438 hasConceptScore W2899687438C509974204 @default.
• W2899687438 hasConceptScore W2899687438C71924100 @default.
• W2899687438 hasIssue "suppl_6" @default.
• W2899687438 hasLocation W28996874381 @default.
• W2899687438 hasLocation W28996874382 @default.
• W2899687438 hasOpenAccess W2899687438 @default.
• W2899687438 hasPrimaryLocation W28996874381 @default.
• W2899687438 hasRelatedWork W2029933304 @default.
• W2899687438 hasRelatedWork W2034544297 @default.
• W2899687438 hasRelatedWork W2128503410 @default.
• W2899687438 hasRelatedWork W2150741177 @default.
• W2899687438 hasRelatedWork W2182919525 @default.
• W2899687438 hasRelatedWork W2367829007 @default.
• W2899687438 hasRelatedWork W2384708512 @default.
• W2899687438 hasRelatedWork W2740663609 @default.
• W2899687438 hasRelatedWork W3194058763 @default.
• W2899687438 hasRelatedWork W92501227 @default.
• W2899687438 hasVolume "20" @default.
• W2899687438 isParatext "false" @default.
• W2899687438 isRetracted "false" @default.
• W2899687438 magId "2899687438" @default.
• W2899687438 workType "article" @default.